Minimal change disease is a kidney disorder that primarily affects children but can also occur in adults, causing protein to leak into urine and leading to swelling throughout the body. Understanding treatment options—both standard approaches and those being investigated in research—can help patients and families navigate this challenging condition.

How Treatment Helps Manage Minimal Change Disease

The main goal of treating minimal change disease is to stop protein from leaking into the urine, reduce swelling, and prevent complications. This condition affects tiny filters in the kidneys called glomeruli, which are clusters of small blood vessels responsible for removing waste from the blood. When these filters become damaged, protein—especially a type called albumin—escapes into the urine instead of staying in the bloodstream where it belongs.^[1]

Treatment plans are tailored to each patient’s age, overall health, and how severe their symptoms are. In children, the condition often responds very well to treatment, and many experience what doctors call a complete remission, meaning their symptoms disappear entirely for a period of time. Adults may take longer to respond and might experience more frequent relapses, where symptoms return after initially improving. The choice of treatment depends on whether this is the first episode, whether the disease has come back after previous treatment, and how well the kidneys are functioning.^[2]

Doctors also consider whether the minimal change disease is primary, meaning it developed on its own without a clear cause, or secondary, meaning it was triggered by another condition such as an infection, certain medications, or even some types of cancer. Secondary minimal change disease requires treating the underlying cause alongside managing the kidney symptoms.^[4]

Standard Treatment Approaches

The cornerstone of treatment for minimal change disease involves medications called corticosteroids, often simply referred to as steroids. These are not the same as the steroids used by athletes to build muscle; medical corticosteroids work by reducing inflammation and calming down the immune system, which appears to play a role in damaging the kidney filters.^[4]

In children, the most commonly prescribed steroid is prednisone, typically given at a dose of 2 milligrams per kilogram of body weight each day, up to a maximum of 80 milligrams daily. Treatment usually continues for several weeks, and remarkably, about 90% of children respond within the first two weeks. Once the protein in the urine disappears—a sign that the treatment is working—doctors continue the medication for an additional six weeks but at lower doses. This extended period helps prevent the disease from coming back too quickly.^[10]

Adults with minimal change disease receive similar steroid treatment, but they tend to respond more slowly than children. While 80% to 90% of adults will eventually respond to steroid therapy, it may take up to 16 weeks to see improvement, compared to just a few weeks in children. During this time, patients need regular monitoring through blood and urine tests to check whether the treatment is working and to watch for side effects.^[10]

Steroids can cause a range of side effects, especially when taken for extended periods. These may include increased appetite and weight gain, mood changes, difficulty sleeping, elevated blood sugar levels, weakening of the bones (a condition called osteoporosis), increased risk of infections, and changes in appearance such as facial swelling. Because of these potential problems, doctors carefully balance the benefits of controlling the kidney disease against the risks of long-term steroid use.^[10]

For patients who experience frequent relapses—meaning their symptoms keep coming back after treatment—or for those who cannot tolerate steroids, doctors may prescribe alternative medications. These include drugs that suppress the immune system in different ways. Calcineurin inhibitors such as cyclosporine and tacrolimus have proven effective in achieving remission while potentially causing fewer side effects than high-dose steroids alone. Some patients receive these medications along with low-dose prednisone for better control.^[10]

Other immunosuppressive medications that may be used include cyclophosphamide, chlorambucil, and mycophenolate mofetil. Each of these works differently to quiet the immune system and prevent it from attacking the kidney filters. The choice among these options depends on the patient’s specific situation, including whether they have tried steroids before, how severe their symptoms are, and what other health conditions they may have.^[12]

Beyond medications that directly treat the kidney problem, doctors also prescribe supportive treatments to manage symptoms and prevent complications. Swelling, one of the most bothersome symptoms, is typically controlled through dietary changes—specifically reducing salt intake—and medications called diuretics or “water pills.” Furosemide is a commonly prescribed diuretic that helps the kidneys remove extra fluid from the body. However, diuretics must be used carefully because patients with minimal change disease can already have low blood volume despite appearing swollen, and removing too much fluid can be dangerous.^[10]

High blood pressure is another common issue that requires treatment. Medications called angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) serve a dual purpose: they lower blood pressure and also reduce the amount of protein leaking into the urine. These medications protect the kidneys from further damage. However, blood pressure and kidney function must be monitored closely when taking ACE inhibitors or ARBs to ensure they’re working safely.^[10]

Patients with minimal change disease also have elevated cholesterol and other fats in their blood, which increases the risk of heart disease. Medications called statins are often prescribed to lower cholesterol levels. Additionally, because the disease increases the risk of blood clots, some patients may need blood-thinning medications, especially if they develop a clot or have other risk factors.^[11]

The duration of treatment varies considerably. Some patients achieve remission and remain symptom-free for years after a single course of treatment. Others experience a relapsing pattern, where symptoms improve with treatment but return weeks, months, or even years later, requiring additional courses of medication. A small percentage of patients become steroid-dependent, meaning they need continuous low-dose steroid therapy to keep symptoms under control. In such cases, doctors work to find the lowest effective dose to minimize side effects while maintaining disease control.^[12]

Emerging Therapies in Clinical Research

Researchers are actively investigating new treatment approaches for minimal change disease, particularly for patients who don’t respond well to standard therapies or who experience frequent relapses. These experimental treatments are studied in clinical trials, which are carefully designed research studies that test whether new therapies are safe and effective before they become widely available.^[1]

One promising area of research involves a medication called rituximab, which targets specific cells in the immune system called B cells. Rituximab is a type of drug known as a monoclonal antibody, meaning it’s designed to attach to and destroy particular immune cells that may be contributing to kidney damage. This medication is already approved for treating other conditions, including certain types of lymphoma and rheumatoid arthritis, but researchers are studying whether it can help patients with minimal change disease who haven’t responded to steroids or who keep relapsing. Early results suggest that rituximab may help maintain remission in some patients with difficult-to-treat disease.^[12]

Scientists are also investigating the underlying mechanisms that cause minimal change disease in the first place. Research suggests that certain immune cells called T cells may release substances that damage the delicate structures in the kidney filters. One area of focus involves cytokines, which are chemical messengers used by immune cells to communicate with each other. Studies have identified several cytokines that appear to be elevated in patients during active disease, including interleukin-12 (IL-12), interleukin-4 (IL-4), and interleukin-13 (IL-13). Understanding these pathways could lead to new treatments that specifically target these molecules.^[7]

Another interesting line of research examines proteins within the kidney filter cells themselves. Scientists have discovered that a protein called synaptopodin, which helps maintain the structure of podocytes (the specialized cells that make up part of the kidney filter), may predict how well a patient will respond to steroid treatment. Patients whose podocytes have higher levels of synaptopodin tend to respond better to steroids. This discovery might eventually help doctors identify which patients are most likely to benefit from standard treatment versus those who might need alternative approaches from the start.^[7]

Clinical trials for kidney diseases typically progress through several phases. Phase I trials focus primarily on safety, testing new treatments in small groups to determine appropriate doses and identify potential side effects. Phase II trials expand to more participants and begin evaluating whether the treatment actually works to reduce symptoms or improve kidney function. Phase III trials are large studies that compare the new treatment directly against the current standard treatment to determine which works better or has fewer side effects. Only after successfully completing these phases can a new treatment be approved for general use.^[1]

Patients interested in participating in clinical trials should discuss this option with their kidney specialist. Trials may be available at academic medical centers and specialized kidney clinics in various locations, including the United States, Europe, and other regions. Eligibility for trials depends on factors such as age, disease severity, previous treatments, and overall health. While clinical trials offer access to cutting-edge therapies, participants must understand both the potential benefits and risks, including the possibility that the experimental treatment may not work or could cause unexpected side effects.^[1]

Most common treatment methods

• Corticosteroid therapy
  • Prednisone is the primary medication, typically given at 2 mg/kg/day in children (maximum 80 mg/day) and similar doses in adults
  • Treatment continues for several weeks initially, with about 90% of children responding within two weeks
  • After initial remission, therapy continues at lower doses for an additional six weeks
  • Adults may require up to 16 weeks to respond to treatment
  • Common side effects include weight gain, mood changes, elevated blood sugar, bone weakening, and increased infection risk
• Immunosuppressive medications
  • Calcineurin inhibitors (cyclosporine, tacrolimus) used for steroid-resistant cases or frequent relapses
  • May be combined with low-dose prednisone for enhanced effectiveness
  • Cyclophosphamide and chlorambucil are alternative options for difficult cases
  • Mycophenolate mofetil serves as another immunosuppressive choice
  • Rituximab is being studied in clinical trials for patients who don’t respond to standard treatments
• Supportive care
  • Loop diuretics like furosemide to manage swelling by removing excess fluid
  • Dietary sodium restriction to help control edema
  • ACE inhibitors and ARBs to lower blood pressure and reduce protein in urine
  • Statins to manage elevated cholesterol levels
  • Anticoagulants if blood clots develop or risk is high
  • Infection prevention measures including vaccinations and prompt treatment of any infections